Literature DB >> 26077086

Understanding the differences among inotropes.

Kurt Lenz1, Fritz Firlinger, Robert Buder.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26077086     DOI： 10.1007/s00134-015-3896-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

Review 1.  Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Catherine L Tacon; John McCaffrey; Anthony Delaney
Journal:  Intensive Care Med       Date:  2011-12-08       Impact factor: 17.440

2.  Levosimendan in cardiogenic shock: the magic drug for every patient?

Authors:  Peter Smetana; Alexander Geppert
Journal:  Crit Care Med       Date:  2007-12       Impact factor: 7.598

3.  Understanding the differences among inotropes.

Authors:  Mattia Arrigo; Alexandre Mebazaa
Journal:  Intensive Care Med       Date:  2015-01-21       Impact factor: 17.440

4.  The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.

Authors:  Catherine Avgeropoulou; Ioanna Andreadou; Sophia Markantonis-Kyroudis; Maritina Demopoulou; Platon Missovoulos; Aris Androulakis; Ioannis Kallikazaros
Journal:  Eur J Heart Fail       Date:  2005-08       Impact factor: 15.534

5.  Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure.

Authors:  C V Leier; P T Heban; P Huss; C A Bush; R P Lewis
Journal:  Circulation       Date:  1978-09       Impact factor: 29.690
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.